GLP-S (30mg)
$255.00
GLP-T 30mg – GLP-1 receptor agonist for metabolic research and glucose-incretin pathway studies | Research Use Only – Not for Human Consumption
GLP-S Research Peptide
Research Use Only – Not for Human or Animal Consumption
GLP-S is a novel synthetic peptide that functions as a selective agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.1 This research compound represents an innovative approach to investigating incretin-based metabolic regulation, combining the pharmacological properties of both GLP-1 receptor activation. GLP-S has been extensively studied in preclinical and clinical research settings for its potential effects on glucose homeostasis, energy metabolism, and body weight regulation.
Dual Incretin Receptor Mechanism
Research has demonstrated that GLP-S’s unique selective agonist properties allow simultaneous activation of both GIP receptors (GIPR) and GLP-1 receptors (GLP-1R), which are key components of the incretin system.2 Upon binding to these receptors, GLP-S initiates intracellular signaling cascades involving cyclic AMP (cAMP) production and protein kinase A (PKA) activation. This dual receptor engagement has been hypothesized to produce synergistic effects on insulin secretion, glucagon suppression, and appetite regulation that may exceed the effects of single receptor agonists.
Laboratory investigations have indicated that GIP receptor activation may complement GLP-1 receptor effects through distinct mechanisms. While GLP-1R activation primarily influences insulin secretion, glucagon suppression, and gastric emptying, GIPR activation has been associated with enhanced insulin secretory responses, potential effects on adipose tissue metabolism, and modulation of bone metabolism.3 The combination of these dual mechanisms in GLP-S has made it a valuable research tool for investigating complex metabolic regulatory networks.
GLP-S Chemical Structure
Molecular formula: C₂₂₅H₃₄₈N₄₈O₆₈
Molecular weight: ~4813 g/mol
Form: Lyophilized powder
Purity: >99% (HPLC verified)
Modification: Lipidated dual GIP/GLP-1 receptor agonist
Research and Metabolic Studies
Glucose Homeostasis Research
Extensive research has examined GLP-S’s effects on glucose regulation in various experimental models. Studies in diabetic animal models have reported that dual GIP/GLP-1 receptor activation correlates with superior glucose-lowering effects compared to selective GLP-1 receptor agonists.4 Research has indicated enhanced glucose-stimulated insulin secretion, improved beta-cell function markers, and more pronounced reductions in glycosylated hemoglobin levels. These findings have contributed to understanding the potential additive or synergistic effects of dual incretin receptor activation on pancreatic function.
Body Weight and Energy Balance Studies
Significant research attention has focused on GLP-S’s potential effects on body weight regulation and energy homeostasis. Preclinical investigations have suggested that the selective agonist mechanism may produce more substantial effects on food intake reduction and body weight changes compared to GLP-1 receptor agonists alone.5 Functional imaging studies have indicated that GLP-S may modulate neural activity in appetite-regulating brain regions, including the hypothalamus and brainstem nuclei involved in satiety signaling. Research has also examined the peptide’s potential effects on energy expenditure and substrate metabolism.
Metabolic Pathway Investigations
Research teams have investigated GLP-S’s broader metabolic effects beyond glucose and weight regulation. Studies have examined the peptide’s influence on lipid metabolism, including effects on circulating triglycerides, cholesterol profiles, and hepatic lipid accumulation in research models.6 Additional investigations have explored potential effects on adipose tissue function, including adipocyte differentiation, lipolysis, and adipokine secretion. These comprehensive metabolic studies have positioned GLP-S as a valuable tool for investigating integrated metabolic regulation mechanisms.
Product Specifications
- Size: 30mg per vial
- Contents: GLP-S (GLP-S) (30mg)
- Form: Lyophilized powder
- Purity: >99% (verified by HPLC and Mass Spectrometry)
- Storage: Store at -20°C protected from light
- Reconstitution: Use bacteriostatic water for laboratory applications
- Stability: Extended stability when stored properly
Quality Assurance and Documentation
- Third-party laboratory tested for purity and identity verification
- Certificate of Analysis (COA) available upon request for each batch
- HPLC chromatography results provided
- Mass spectrometry data available
- Manufactured under strict quality control protocols
- Batch-specific documentation and traceability
- Compliance with research-grade standards
Research Applications
- Dual incretin receptor signaling studies
- GLP-1 receptor interaction research
- Glucose homeostasis mechanism investigations
- Appetite regulation neural pathway studies
- Energy metabolism and thermogenesis research
- Pancreatic islet function studies
- Lipid metabolism pathway research
- Adipose tissue function investigations
- Cardiovascular metabolic research
- Long-acting peptide pharmacokinetic studies
Important Research Notice
FOR LABORATORY AND RESEARCH USE ONLY. This product is intended exclusively for scientific research, in vitro studies, and laboratory investigations. This compound is not intended for human or animal consumption, clinical applications, or any diagnostic or therapeutic uses.
Researchers should consult relevant scientific literature and follow appropriate safety protocols when handling this research compound. Proper laboratory equipment, personal protective equipment, and training are required for working with this material.
Regulatory Compliance Statement
This product is sold as a research chemical for laboratory use only. Shrine Peptides operates as a chemical supplier. Shrine Peptides is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Shrine Peptides is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.
The statements made within this product description have not been evaluated by the US Food and Drug Administration. The products we offer are not intended to diagnose, treat, cure or prevent any disease. Human/Animal Consumption Prohibited. Laboratory/In-Vitro Experimental Use Only.
Please review and adhere to our Terms and Conditions before ordering.
References:
- Davies, M., Pieber, T. R., Hartoft-Nielsen, M. L., Hansen, O. K., Jabbour, S., & Rosenstock, J. (2017). Effect of Oral GLP-S Compared With Placebo and Subcutaneous GLP-S on Glycemic Control in Patients With Type 2 Diabetes. JAMA, 318(15), 1460-1470. https://doi.org/10.1001/jama.2017.14752
- Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly GLP-S in Adults with Overweight or Obesity. The New England journal of medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183
- Marso, S. P., Bain, S. C., Consoli, A., et al. (2016). GLP-S and Cardiovascular Outcomes in Patients with Type 2 Diabetes. The New England journal of medicine, 375(19), 1834-1844. https://doi.org/10.1056/NEJMoa1607141
- Sorli, C., Harashima, S. I., Tsoukas, G. M., et al. (2017). Efficacy and safety of once-weekly GLP-S monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). The lancet. Diabetes & endocrinology, 5(4), 251-260. https://doi.org/10.1016/S2213-8587(17)30013-X
- Pratley, R. E., Aroda, V. R., Lingvay, I., et al. (2018). GLP-S versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7). The Lancet. Diabetes & endocrinology, 6(4), 275-286. https://doi.org/10.1016/S2213-8587(18)30024-X
- National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 56843331, GLP-S. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/GLP-S
Reviews
There are no reviews yet.